Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.
Yuan-Mao LinRyosuke TaijiMarco CalandriBruno C OdisioPublished in: Current oncology reports (2021)
RAS mutation is a prognosticator for patients with colorectal liver metastases. Several promising serum metabolites, gene signatures, circulating tumor nucleotides, and peptides are being evaluated for patients with hepatocellular carcinoma. Ki-67 and RAS mutation are independent risk factors for local tumor progression in the ablation of lung cancer. The relevant interplay between specific tumor biomarkers and IO loco-regional therapies outcomes has brought a new vision in the management of cancer. Further evolution of personalized interventional oncology accordingly to tumor biomarkers should improve oncologic outcomes for patients receiving IO therapies.
Keyphrases
- liver metastases
- circulating tumor
- palliative care
- genome wide
- ms ms
- prostate cancer
- squamous cell carcinoma
- poor prognosis
- gene expression
- papillary thyroid
- circulating tumor cells
- dna methylation
- cell free
- insulin resistance
- atrial fibrillation
- radical prostatectomy
- radiation therapy
- copy number
- squamous cell
- rectal cancer
- minimally invasive
- amino acid
- glycemic control
- catheter ablation